RWJ 445380

Drug Profile

RWJ 445380

Alternative Names: RWJ-445380

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation
  • Class Antirheumatics
  • Mechanism of Action Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 30 Nov 2006 Phase-II clinical trials in Rheumatoid arthritis in Argentina (PO)
  • 30 Nov 2006 Phase-II clinical trials in Rheumatoid arthritis in Czech Republic (PO)
  • 30 Nov 2006 Phase-II clinical trials in Rheumatoid arthritis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top